The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

British pharma giant GSK plc has entered into a definitive agreement to acquire Boston-based clinical-stage biopharmaceutical specialist Nuvalent, Inc. for $10.6 billion in cash. The transaction stands as the second-largest biopharma takeover of the year, providing GSK with an immediate, high-value footprint in the targeted non-small cell lung cancer market.

The deal includes three product lines headlined by two late-stage, potentially best-in-class tyrosine kinase inhibitors under priority review by the U.S. Food and Drug Administration, with regulatory approval rulings slated before the end of the year.

GSK will commence an official tender offer within ten business days to acquire all outstanding Class A and Class B common shares of Nuvalent at a cash price of $124 per share, under the terms of the agreement. The offer represents a 40% premium to Nuvalent's final pre-announcement closing price and a 26% premium over its thirty-day volume-weighted average price. The aggregate equity value of the transaction sits at $10.6 billion, representing a net corporate investment of $9.4 billion once accounting for Nuvalent’s existing cash reserves. GSK confirms the transaction will be financed primarily through new and available debt facilities, preserving its investment-grade credit rating.

The deal centers on Nuvalent’s two lead oncology compounds, zidesamtinib and neladalkib. Both small molecules are designed as next-generation, highly selective oral therapies for non-small cell lung cancer, a condition that predominantly impacts working-age, non-smoking adults between forty and fifty years old. Zidesamtinib acts as a potent ROS1 blocker, carrying an explicit FDA target decision date of September 18, 2026. Neladalkib functions as an ALK mutation inhibitor, with its target FDA review date established for November 27, 2026.

Both pipelines have already secured formal Breakthrough Therapy and Orphan Drug designations from U.S. regulators. Pivotal trial data delivered at major lung cancer symposia demonstrate that both compounds possess enhanced blood-brain barrier penetration capable of neutralizing brain metastases while displaying broad durability against standard treatment-resistant mutations. If approved, GSK aims to initiate commercial launches before the close of 2026.

The transaction also includes NVL-330, a selective HER2 inhibitor currently navigating Phase 1 human trials for HER2-altered lung cancers, alongside an undisclosed preclinical portfolio of precision kinase programs. The transaction is scheduled to close in the third quarter of 2026, subject to customary antitrust clearances and the successful tendering of a majority of Nuvalent's Class A common stock.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

This transaction represents a significant consolidation step within the global oncology sector, emphasizing a major industry shift where large pharmaceutical companies use financial reserves to absorb heavily de-risked, late-stage biotechnology targets with imminent commercial sight-lines.

For GSK Chief Executive Officer Luke Miels, the transaction resolves a pressing strategic timeline. The group is aggressively rebalancing its portfolio ahead of the impending 2028 to 2030 patent expiration window for its multi-billion-pound blockbuster HIV therapy, dolutegravir. By acquiring Nuvalent, GSK establishes an instant lung cancer franchise capable of lifting its corporate revenue performance from 2027 onward, helping support its broader target to surpass forty billion pounds in annual group sales by 2031. Wall Street analysts note that the acquisition presents very low antitrust execution risk in Washington due to the lack of overlap between the two firms' existing pipelines.

And the Nuvalent small-molecule portfolio serves as a vital clinical anchor for GSK's broader oncology ambitions. The company intends to use the newly acquired lung cancer infrastructure to execute rapid combination trials with Ris-Rez, its proprietary B7-H3 targeted antibody-drug conjugate that is currently in advanced Phase 3 clinical development. By layering highly selective oral kinase inhibitors with advanced antibody-drug conjugates, GSK aims to construct a highly defensive oncology platform that addresses the severe neurological and metabolic side effects associated with legacy chemotherapy standard-of-care treatments.

While the deal leaves GSK's core full-year operating profit growth outlook unchanged at seven to nine percent, it will create minor dilution to core earnings per share through 2028 to account for transactional carrying costs and the absorption of Nuvalent's royalty obligations to Royalty Pharma and Deerfield. However, the premium paid highlights the commercial value of capturing highly targeted therapies that hit validated oncological pathways.

The immediate corporate focus shifts to the 10-day regulatory window, during which GSK will formally launch its public tender offer to private shareholders. Institutional arb desks will monitor the collection rate to ensure the majority threshold of Class A common shares is met ahead of the final merger closing in the third quarter.

The ultimate commercial catalyst for the stock is September 18, when the FDA delivers its final approval verdict on zidesamtinib. If the drug secures its commercial label on schedule, it will trigger an immediate product launch across the U.S., followed closely by the final regulatory assessment for neladalkib in late November. If both assets successfully transition from the lab to the clinic before winter, GSK will enter 2027 with a dual-engine blockbuster franchise capable of reshaping standard lung cancer protocols worldwide.